Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
Author(s) -
Sushmita D. Lahiri,
Grant K. Walkup,
James Whiteaker,
Tiffany Palmer,
Kathy McCormack,
M. Angela Tanudra,
Tory J. Nash,
Jason Thresher,
Michele Johnstone,
Laurie Hajec,
Stephania Livchak,
Robert E. McLaughlin,
Richard A. Alm
Publication year - 2015
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkv004
Subject(s) - ceftazidime/avibactam , avibactam , ceftazidime , pseudomonas aeruginosa , microbiology and biotechnology , mutant , biology , beta lactamase inhibitors , chemistry , bacteria , biochemistry , antibiotics , gene , genetics
Pseudomonas aeruginosa is an important nosocomial pathogen that can cause a wide range of infections resulting in significant morbidity and mortality. Avibactam, a novel non-β-lactam β-lactamase inhibitor, is being developed in combination with ceftazidime and has the potential to be a valuable addition to the treatment options for the infectious diseases practitioner. We compared the frequency of resistance development to ceftazidime/avibactam in three P. aeruginosa strains that carried derepressed ampC alleles.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom